NervGen Pharma Corp. Common stock (NGEN)

Price$1.94

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)36.69%

Price vs S&P 500 (4W)-5.18%

VGM Score55.73

Market Capitalization$285.66M

All Metrics

Book Value / Share (Quarterly)$0.01

P/TBV (Annual)7.21x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.17

Price vs S&P 500 (YTD)-30.33%

EPS (TTM)$-0.26

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-0.26

EPS (Annual)$-0.26

ROI (Annual)-150.77%

Cash / Share (Quarterly)$0.11

ROA (Last FY)-86.79%

EBITD / Share (TTM)$-0.26

ROE (5Y Avg)-127.95%

Cash Flow / Share (Annual)$-0.22

P/B Ratio283.61x

P/B Ratio (Quarterly)146.47x

Net Income / Employee (Annual)$-1,740,205

Net Interest Coverage (TTM)-3.86x

ROA (TTM)-158.08%

EPS Incl Extra (Annual)$-0.26

Current Ratio (Annual)2.27x

Quick Ratio (Quarterly)0.77x

3-Month Avg Trading Volume0.11M

52-Week Price Return89.34%

Tangible BV / Share (Quarterly)$0.01

52-Week High$8.49

EPS Excl Extra (Annual)$-0.26

26-Week Price Return39.57%

Quick Ratio (Annual)2.25x

13-Week Price Return-12.12%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)0.79x

Enterprise Value$277.45M

Revenue / Employee (Annual)$0

Cash / Share (Annual)$0.28

3-Month Return Std Dev61.49%

Net Income / Employee (TTM)$-1,871,485

ROE (Last FY)-153.94%

Net Interest Coverage (Annual)-2.99x

EPS Basic Excl Extra (Annual)$-0.26

Total Debt / Equity (Quarterly)0.06x

EPS Incl Extra (TTM)$-0.26

ROI (TTM)-392.44%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.16

Price vs S&P 500 (52W)70.47%

Year-to-Date Return-32.94%

5-Day Price Return-6.36%

EPS Normalized (Annual)$-0.26

ROA (5Y Avg)-102.74%

Month-to-Date Return-3.74%

Cash Flow / Share (TTM)$-0.24

EBITD / Share (Annual)$-0.27

LT Debt / Equity (Annual)1.46x

ROI (5Y Avg)-127.32%

LT Debt / Equity (Quarterly)2.53x

EPS Basic Excl Extra (TTM)$-0.26

P/TBV (Quarterly)216.86x

P/B Ratio (Annual)6.97x

Book Value / Share (Annual)$0.17

Price vs S&P 500 (13W)-9.42%

Beta1.45x

ROE (TTM)-399.62%

52-Week Low$2.57

mGradeC

vgmGradeC

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
NGENNervGen Pharma Corp. Common stock	—	—	C	$1.94
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

NervGen Pharma is a clinical-stage biotech company developing therapies to enable the nervous system to repair itself following injury or disease. The company's initial focus is spinal cord injury, with lead candidates NVG-291 and NVG-300 in its pipeline.